It is with great pleasure that I share with you our 2018 Activity Report, which reflects the progress we have made in addressing Gram-negative drug-resistant infections in children, newborns with sepsis, and sexually-transmitted infections.
2019 is an important year for taking concrete action to address antimicrobial resistance. For our part, we are launching an ambitious, new strategy and are redoubling our efforts to develop and deliver new antibiotic treatments.
I look forward to continued collaboration with our founding partners, the World Health Organization and Drugs for Neglected Diseases initiative, as well as with all of you, our fellow colleagues, partners and donors on this urgent challenge.
Dr Manica Balasegaram